Top

Published in:

01-08-2015 | Original Investigation

A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients

Authors: Verónica Rodriguez-Nava, Stéphane Durupt, Sandra Chyderiotis, Anne-Marie Freydière, Judith Karsenty, Michèle de Montclos, Philippe Reix, Isabelle Durieu, Raphaele Nove-Josserand, Raphael Chiron, François Bremont, Laurent Têtu, Marlène Murris, Dominique Terru, Sylvain Godreuil, Emmanuelle Bergeron, Jean Freney, Patrick Boiron, François Vandenesch, Hélène Marchandin, Christine Segonds, Anne Doléans-Jordheim

Published in: Medical Microbiology and Immunology | Issue 4/2015

Abstract

Some bacterial species recovered from the airways of cystic fibrosis (CF) patients are indisputably associated with lung infections, whereas the clinical relevance of others, such as Nocardia spp., remains unclear. Sixteen French CF cases of colonization/infection with Nocardia spp. were reviewed in order to evaluate the epidemiology, the clinical impact and the potential treatment of these bacteria, and results were compared to those of the literature. Five Nocardia species were identified, Nocardia cyriacigeorgica being the major species (50 % of cases). At first isolation, Nocardia was the sole pathogen recovered in six patients. Seven patients presented pulmonary exacerbation. For 12 patients, antimicrobial treatment against Nocardia was started immediately, mainly based on cotrimoxazole (6 of the 12 cases). In this study, we highlight the heterogeneity of the clinical management of Nocardia spp. in CF. Guidelines for the clinical management of Nocardia infections in CF patients are proposed.

Ratjen FA (2009) Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 54:595–605PubMedCrossRef

Harrison F (2007) Microbial ecology of the cystic fibrosis lung. Microbiology 153:917–923PubMedCrossRef

Lipuma JJ (2010) The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 23:299–323PubMedCentralPubMedCrossRef

Coenye T, Goris J, Spilker T, Vandamme P, LiPuma JJ (2002) Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol 40:2062–2069PubMedCentralPubMedCrossRef

Barrio MI, Martinez MC, Prados C, Giron RM, Maiz L, Martinez MT (2008) Isolation of Nocardia species in patients with cystic fibrosis. Arch Bronconeumol 44:109–112PubMedCrossRef

Petersen BE, Jenkins SG, Yuan S, Lamm C, Szporn AH (2007) Nocardia farcinica isolated from bronchoalveolar lavage fluid of a child with cystic fibrosis. Pediatr Infect Dis J 26:858–859PubMedCrossRef

Beucher J, Belleguic C, Brinchault G, Deneuville E, Donnio PY, Roussey M (2010) Nocardia farcinica infection in a patient with cystic fibrosis. Rev Mal Respir 27:76–79PubMedCrossRef

Rodriguez-Nava V, Lebeaux D, Lortholary O, Boiron P (2013) Nocardia. In: Freney J, Renaud F, Leclercq R, Riegel P (eds) Précis de bactériologie clinique, 2nd edn. Eska, Paris, p 1764

Corti ME, Villafane-Fioti MF (2003) Nocardiosis: a review. Int J Infect Dis 7:243–250PubMedCrossRef

10.

Thorn ST, Brown MA, Yanes JJ, Sherrill DL, Pugmire J, Anderson KA, Klotz SA (2009) Pulmonary nocardiosis in cystic fibrosis. J Cyst Fibros 8:316–320PubMedCrossRef

11.

Aravantagi A, Patra KP, Broussard M, Jones K (2012) A case of Nocardia transvalensis pneumonia in a 19-year-old cystic fibrosis patient. Lung India 29:283–285PubMedCentralPubMedCrossRef

12.

Kohn AS, Conrad DA (2003) Recurrent fevers in a five-year-old boy with cystic fibrosis. Pediatr Infect Dis J 22(474):478–479

13.

Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. N Engl J Med 331:637–642PubMedCrossRef

14.

Schlaberg R, Huard RC, Della-Latta P (2008) Nocardia cyriacigeorgica, an emerging pathogen in the United States. J Clin Microbiol 46:265–273PubMedCentralPubMedCrossRef

15.

Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr (2006) Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 19:259–282PubMedCentralPubMedCrossRef

16.

Rodriguez-Nava V, Couble A, Devulder G, Flandrois JP, Boiron P, Laurent F (2006) Use of PCR-restriction enzyme pattern analysis and sequencing database for hsp65 gene-based identification of Nocardia species. J Clin Microbiol 44:536–546PubMedCentralPubMedCrossRef

17.

Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389–3402PubMedCentralPubMedCrossRef

18.

French Society for Microbiology (CASFM). Les recommandations du Comité de l’Antibiogramme de la Société Française de Microbiologie, 2013

19.

Clinical and Laboratory Standars Institute (CLSI). Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes; approved standard-second edition, 2011. Clinical and Laboratory Standards Institute

20.

Lumb R, Greville H, Martin J, Sangster N, Holmes M (2002) Nocardia asteroides isolated from three patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 21:230–233PubMedCrossRef

21.

Pattison SH, Rogers GB, Crockard M, Elborn JS, Tunney MM (2013) Molecular detection of CF lung pathogens: current status and future potential. J Cyst Fibros 12:194–205PubMedCrossRef

22.

Lewis KE, Ebden P, Wooster SL, Rees J, Harrison GA (2003) Multi-system infection with Nocardia farcinica-therapy with linezolid and minocycline. J Infect 46:199–202PubMedCrossRef

23.

Ambrosioni J, Lew D, Garbino J (2010) Nocardiosis: updated clinical review and experience at a tertiary center. Infection 38:89–97PubMedCrossRef

24.

Conville PS, Brown-Elliott BA, Wallace RJ Jr, Witebsky FG, Koziol D, Hall GS, Killian SB, Knapp CC, Warshauer D, Van T, Wengenack NL, Deml S, Woods GL (2012) Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species. J Clin Microbiol 50:1270–1280PubMedCentralPubMedCrossRef

25.

Conville PS, Brown JM, Steigerwalt AG, Brown-Elliott BA, Witebsky FG (2008) Nocardia wallacei sp. nov. and Nocardia blacklockiae sp. nov., human pathogens and members of the “Nocardia transvalensis Complex”. J Clin Microbiol 46:1178–1184PubMedCentralPubMedCrossRef

26.

Schlaberg R, Fisher MA, Hanson KE (2014) Susceptibility profiles of Nocardia isolates based on current taxonomy. Antimicrob Agents Chemother 58:795–800PubMedCentralPubMedCrossRef

27.

McNeil MM, Brown JM (1994) The medically important aerobic actinomycetes: epidemiology and microbiology. Clin Microbiol Rev 7:357–417PubMedCentralPubMed

28.

Goodfellow M (1998) Nocardia and related genera. In: Balows A, Duerden BI (ed) Topley and Wilson’s microbiology and microbial infections, 9th edn. London, pp 463–489

29.

Bittar F, Stremler N, Audie JP, Dubus JC, Sarles J, Raoult D, Rolain JM (2010) Nocardia farcinica lung infection in a patient with cystic fibrosis: a case report. J Med Case Rep 4:84PubMedCentralPubMedCrossRef

30.

Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, Kwak EJ, Paterson DL (2007) Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 44:1307–1314PubMedCrossRef

31.

van Burik JA, Hackman RC, Nadeem SQ, Hiemenz JW, White MH, Flowers ME, Bowden RA (1997) Nocardiosis after bone marrow transplantation: a retrospective study. Clin Infect Dis 24:1154–1160PubMedCrossRef

32.

Ferrer A, Llorenc V, Codina G, de Gracia-Roldan J (2005) Nocardiosis and bronchiectasis. An uncommon association? Enferm Infecc Microbiol Clin 23:62–66PubMedCrossRef

33.

Verroken A, Janssens M, Berhin C, Bogaerts P, Huang TD, Wauters G, Glupczynski Y (2010) Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nocardia species. J Clin Microbiol 48:4015–4021PubMedCentralPubMedCrossRef

34.

Couble A, Rodriguez-Nava V, de Montclos MP, Boiron P, Laurent F (2005) Direct detection of Nocardia spp. in clinical samples by a rapid molecular method. J Clin Microbiol 43:1921–1924PubMedCentralPubMedCrossRef

35.

Taj-Aldeen SJ, Deshmukh A, Doiphode S, Wahab AA, Allangawi M, Almuzrkchi A, Klaassen CH, Meis JF (2013) Molecular identification and susceptibility pattern of clinical Nocardia species: emergence of Nocardia crassostreae as an agent of invasive nocardiosis. Can J Infect Dis Med Microbiol 24:e33–e38PubMedCentralPubMed

36.

Dasgupta B, Brown N, Rennie R, Sand C (2004). Presented at the Canadian association for microbiology and infectious diseases annual conference, Regina, Saskatchewan, Nov 7–10

37.

Pablo Y, Asher T (1994) Pathological cases of the month. Nocardia asteroides infection in cystic fibrosis. Arch Pediatr Adolesc Med 148:209–210PubMedCrossRef

Title: A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients
Authors: Verónica Rodriguez-Nava
Stéphane Durupt
Sandra Chyderiotis
Anne-Marie Freydière
Judith Karsenty
Michèle de Montclos
Philippe Reix
Isabelle Durieu
Raphaele Nove-Josserand
Raphael Chiron
François Bremont
Laurent Têtu
Marlène Murris
Dominique Terru
Sylvain Godreuil
Emmanuelle Bergeron
Jean Freney
Patrick Boiron
François Vandenesch
Hélène Marchandin
Christine Segonds
Anne Doléans-Jordheim
Publication date: 01-08-2015
Publisher: Springer Berlin Heidelberg
Published in: Medical Microbiology and Immunology / Issue 4/2015
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-014-0360-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey

Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors

Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines

Neutrophil gelatinase-associated lipocalin and innate immune responses to bacterial infections

Expression profile and histological distribution of IFITM1 and IFITM3 during H9N2 avian influenza virus infection in BALB/c mice

Influence of a probiotic Lactobacillus casei strain on the colonisation with potential pathogenic streptococci and Staphylococcus aureus in the nasopharyngeal space of healthy men with a low baseline NK cell activity

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials